New Biopharma IPOs Show Modest Step Up In Step-Ups
This article was originally published in Start Up
Executive Summary
The IPO drumbeat for drug companies is slow but steady, with valuations looking a bit stronger than 2011. But insider participation, haircuts and dilution are still the order of the day.